GLP-1 weight loss

GLP-1 medicines act like a gut hormone involved in appetite. They reduce hunger and slow stomach emptying. Tirzepatide also acts on another hormone pathway called GIP. These are prescriptions for long-term care.

FDA-approved brands for long-term weight management in eligible adults include:

• Semaglutide: Wegovy, including tablet and injection forms. Wegovy HD is a higher-dose injection for eligible adults.
• Tirzepatide: Zepbound.
• Liraglutide: Saxenda.
• Orforglipron: Foundayo, a daily tablet.

Ozempic and Rybelsus contain semaglutide. Mounjaro contains tirzepatide. Victoza contains liraglutide. Those brands are approved for type 2 diabetes, not weight loss. FDA-approved prescribing for weight loss uses the weight-management product and its own criteria. Using a diabetes brand for weight loss is off-label. That means the FDA has not approved that use.

The products and forms above have different instructions and eligibility rules. A prescriber should choose the product and review its current label with you.

A licensed clinician with authority to prescribe in Arizona must be responsible for your care. That can be a doctor, nurse practitioner or physician assistant working within their prescribing authority.

An examination and medical history come before the prescription. Expect a review of your medicines and pregnancy plans. Scheduled follow-ups should check side effects, nutrition and whether treatment remains appropriate. Tests should follow your medical needs.

You need a named person to contact between visits. If nobody checks on you between refills, ongoing assessment is missing.

Compounded means a pharmacy or clinician makes a preparation for a patient's needs. It is not the FDA-approved branded product.

Shortages allowed some compounding of semaglutide and tirzepatide copies under federal rules. The FDA has since declared those injection shortages resolved. That shortage exception no longer applies. Other limited compounding exceptions remain.

Compounded drugs do not go through FDA review for safety, effectiveness or quality before sale. You give up that product-level review. They are not FDA-approved generics.

The FDA has reported dosing errors with compounded semaglutide. Some patients needed hospital care. Errors included patients measuring incorrectly and clinicians miscalculating amounts. The agency has also warned about semaglutide sodium and semaglutide acetate. These are different ingredients from the semaglutide in approved products.

Ask to see the original label and who made it. An approved product can also come in a vial. The container alone does not settle it.

The prescriber checks your health against the chosen product's criteria. Adult weight-management indications cover obesity, or overweight with a weight-related condition. High blood pressure is one example. Your medical history still matters. Meeting the weight criteria does not automatically make a medicine appropriate.

These products are approved alongside reduced-calorie eating and increased physical activity.

The prescribed amount increases in steps to limit stomach side effects. This takes months for some products and weeks for others. The schedule depends on the product and how you tolerate it.

Wegovy and Zepbound injections are weekly. Saxenda injections are daily. You can give these at home after instruction. Wegovy also comes as a daily pill. Foundayo is a daily pill.

Nausea, vomiting, diarrhea, constipation and stomach pain are common. Some people stop treatment because of side effects. Taking a tablet or giving an injection takes little time; side effects can last longer.

The labels warn about pancreas inflammation, gallbladder disease, kidney injury from dehydration and serious allergic reactions. Low blood sugar is another risk, especially with insulin or certain diabetes medicines. Severe or persistent abdominal pain needs prompt medical attention. Trouble breathing or swelling of the face, lips, tongue or throat needs emergency care.

Weight regain is common after stopping. Studies of semaglutide and tirzepatide found substantial regain after withdrawal. The plan needs to cover stopping as well as starting.

Wegovy, Zepbound, Saxenda and Foundayo carry boxed warnings about possible thyroid tumors. Whether they cause these tumors in people is unknown.

Their labels rule them out with a personal or family history of medullary thyroid cancer. They also rule them out with multiple endocrine neoplasia syndrome type 2, called MEN 2. A serious allergy to the prescribed medicine or its ingredients is another exclusion.

The weight-loss labels say to stop when pregnancy is recognized. Discuss pregnancy plans and breastfeeding before starting. Zepbound and Foundayo can reduce the effectiveness of birth control pills. Their labels include backup contraception instructions.

These medicines are not recommended with severe stomach-emptying problems called gastroparesis. Review pancreas, kidney and diabetes-related eye problems with the prescriber. Planned anesthesia also needs discussion because stomach contents can enter the lungs.

• Who is prescribing, and what Arizona license gives them prescribing authority?
• Is this the FDA-approved product, and what exactly is on its label?
• What is the monitoring plan, and who answers between visits?
• What happens if I stop?
• What is the total cost over a year, including medicine, visits and tests?

The product, insurance coverage and follow-up care affect your bill. Whether the medicine is compounded also changes the quote.

Insurance coverage varies by plan. Some plans cover weight-management medicines. Others exclude them. Ask your insurer about the exact product and your reason for taking it before paying.

The medicine is a monthly cost for as long as you take it. An introductory price is temporary.

This is a guide, not medical advice. Whether a treatment is right for you is a decision for a licensed provider who has examined you.